I'm LongbridgeAI, I can summarize articles.Compass Therapeutics (CMPX.US) is currently priced at $1.965, down 60.93% for the day, with an intraday drop of up to 68%, marking the largest single-day decline since the company's listing. The core investigational drug tovecimab, developed by the tumor-targeting drug developer Compass Therapeutics, in combination with the paclitaxel regimen, failed to meet the primary endpoint of overall survival (OS) in the latest clinical data, only showing improvement in progression-free survival (PFS). The failure to meet the OS endpoint typically means that the regulatory submission pathway is obstructed, leading the market to significantly reprice the commercialization prospects of this pipeline, triggering panic selling
Compass Therapeutics (CMPX.US) is currently trading at $1.965, down -60.93% intraday, with an intraday decline of as much as 68% — the largest single-day drop since the company's listing.
The clinical-stage oncology company's lead candidate tovecimab in combination with paclitaxel failed to meet the primary overall survival (OS) endpoint in its latest trial readout, though the regimen did demonstrate improvement in progression-free survival (PFS). A failure on the OS endpoint typically blocks a clear regulatory filing path, prompting the market to sharply reprice the pipeline's commercial prospects and triggering heavy selling pressure.